Chinese biotech Akeso released positive Phase III clinical trial results demonstrating significant survival benefits of its PD-1xVEGF bispecific antibody ivonescimab in non-small cell lung cancer patients progressing after EGFR-targeted therapies. Additionally, Akeso’s gumokimab and manfidokimab successfully met primary efficacy endpoints in ankylosing spondylitis and moderate-to-severe atopic dermatitis, respectively, bolstering its immunology pipeline. These results position Akeso for upcoming regulatory submissions and strengthen their competitive stance against established immunotherapies such as Merck’s Keytruda.